샘플 요청 목록

 카트 문의
시장보고서
상품코드
1480391

세계의 마우스 모델 시장

Mice Model
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 173 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

마우스 모델 세계 시장은 2030년까지 26억 달러에 달할 전망

2023년에 19억 달러로 추정되는 마우스 모델 세계 시장은 2023-2030년 분석기간 동안 CAGR 5.2%로 성장하여 2030년에는 26억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 CRISPR/CAS9 테크놀러지는 CAGR 6.5%를 기록하고, 분석기간 종료까지 9억 7,670만 달러에 달할 것으로 예측됩니다. 마이크로인젝션 기술 부문은 향후 7년간 CAGR이 4.3%로 예측됩니다.

미국 시장은 4억 9,000만 달러로 추정, 중국은 CAGR 8.1%로 성장 예측

미국의 마우스 모델 시장은 2023년에는 4억 9,000만 달러에 달할 것으로 추정됩니다. 세계 2위 경제 대국인 중국은 2023년부터 2030년까지 CAGR 8.1%로 성장하여 2030년에는 6억 310만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지리적 시장으로는 일본과 캐나다가 있고, 각각 2023년부터 2030년까지 2.6%와 4.8%의 성장이 예측됩니다. 유럽에서는 독일이 CAGR 약 3.1%로 성장할 것으로 예측됩니다. 호주, 인도, 한국 등의 국가가 견인하는 아시아태평양의 시장은 2030년까지 3억 6,800만 달러에 달할 것으로 예측됩니다.

2024년에 새롭게 선보이는 흥미로운 보고서 기능 소개

인플루언서 참여 통계에 대한 풀 액세스

디지털 아카이브와 "MarketGlass" 조사 플랫폼에 무료로 액세스할 수 있습니다. 당사의 독자적인 MarketGlass 플랫폼은 전 세계 전문가들의 창의성과 시장 지식을 통합적이고 협력적으로 발휘할 수 있도록 지원합니다. 당사의 최첨단 도구는 시장 진입자의 프라이버시와 신원을 보호하면서 세계적 수준의 시장 전망을 제공합니다. 보고서의 수치, 통계 및 시장 설명은 이 분야의 전문가와 영향력 있는 사람들이 공유한 완전히 선별된 인사이트를 기반으로 합니다.

실시간 데이터 시뮬레이터 도구와 맞춤형 보고서 작성 기능을 갖춘 인터랙티브 설문 조사에 참여할 수 있습니다.

기업 간 스마트한 의견 교환을 위한 피어 협업 인터랙티브 플랫폼에 대한 풀 클라이언트 액세스

1년간 무료 보고서 업데이트

주요 기업의 세계 시장 점유율을 포함한 경쟁 커버리지

여러 지역에 걸친 기업의 시장 입지 분석(호조/활발/틈새/마이너)

전문가/인플루언서 인터뷰, 팟캐스트, 언론 발표, 이벤트 기조연설 유튜브 동영상에 대한 접근성

2024년 세계 경제에 대한 기대

통화 긴축과 이에 따른 금리 상승으로 인한 지정학적, 경제적 불안정성이 2024년 격동적인 상황을 만들어 낼 것으로 보입니다. 중동의 적대 행위와 점점 더 잦아지는 기후 재해 등 여러 요인들이 회복의 길에 계속 압력을 가할 것으로 예상됩니다. 위험요인이 있는 반면, 디플레이션 조짐이 강해지고, 완고한 인플레이션에 대한 불안감이 완화되고, 공급망이 정상화되고, 에너지 비용 변동에도 불구하고 물가가 완만하게 상승하는 등 몇 가지 긍정적인 요인도 나타나고 있습니다. 인도와 미국을 비롯한 G21 국가들의 선거는 자본 흐름과 투자 전략에 영향을 미칠 수 있습니다. 인도가 글로벌 투자처로 주목받고 있는 가운데, 미국에 기반을 둔 하이테크 기업들은 역동적인 인재와 자본 생태계에 힘입어 계속 우위를 점할 것으로 보입니다. 실리콘밸리를 비롯한 하이테크 기회는 국내 경제가 둔화되긴 했지만 여전히 견고하고 규제 환경이 잘 정비되어 있어 높은 성장 잠재력을 추구하는 투자자들에게 여전히 매력적일 것으로 보입니다. 유럽은 긴축정책과 경기침체 리스크와의 싸움이 계속되고 있으며, 영국은 2024년 경기침체 리스크가 가장 높은 국가로 가장 어려운 전망을 보이고 있습니다. 중국은 정부 지출과 개인 소비 개선에 힘입어 성장세를 이어갈 것으로 예상되는 와일드카드가 될 것입니다. 불안정한 환경은 투자자와 기업 모두에게 기회와 도전을 동시에 가져다 줄 것으로 보입니다. 변동성을 성장의 촉매제로 받아들이고, 민첩한 투자 판단과 전략적 선견지명이 생존을 위한 핵심 요소로 작용할 것입니다.

조사 대상 기업 사례(총 46건)

  • Charles River Laboratories International, Inc.
  • Envigo, Inc.
  • Genoway S.A.
  • Harbour Antibodies BV
  • Horizon Discovery Group PLC
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs
  • Laboratory Corporation of America Holdings(LabCorp)
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • Trans Genic, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 24.05.22

Global Mice Model Market to Reach $2.6 Billion by 2030

The global market for Mice Model estimated at US$1.9 Billion in the year 2023, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. CRISPR / CAS9 Technology, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$976.7 Million by the end of the analysis period. Growth in the Microinjection Technology segment is estimated at 4.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $490 Million, While China is Forecast to Grow at 8.1% CAGR

The Mice Model market in the U.S. is estimated at US$490 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$603.1 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 4.8% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$368 Million by the year 2030.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 46 Featured) -

  • Charles River Laboratories International, Inc.
  • Envigo, Inc.
  • Genoway S.A.
  • Harbour Antibodies BV
  • Horizon Discovery Group PLC
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs
  • Laboratory Corporation of America Holdings (LabCorp)
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • Trans Genic, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Mice Model - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Microinjection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Microinjection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Microinjection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Embryonic Stem Cell Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Embryonic Stem Cell Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Embryonic Stem Cell Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Nuclear Transfer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Nuclear Transfer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Nuclear Transfer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Breeding by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Breeding by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Breeding by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cryopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cryopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Cryopreservation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Mice Model Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for CRISPR / CAS9 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for CRISPR / CAS9 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for CRISPR / CAS9 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Quarantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Quarantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Quarantine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Model-In Licensing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Model-In Licensing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Model-In Licensing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: World 16-Year Perspective for Central Nervous System (CNS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Immunology & Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Immunology & Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: World 16-Year Perspective for Immunology & Inflammation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: World 16-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: World 16-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: USA 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • JAPAN
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • CHINA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: China 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: China 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: China 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • EUROPE
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Mice Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Mice Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • FRANCE
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: France 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: France 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: France 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • GERMANY
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Germany 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Germany 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Germany 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Italy 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Italy 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Italy 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: UK 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: UK 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: UK 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Spain 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Spain 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Spain 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Russia 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Russia 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Russia 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Europe 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Europe 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Europe 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Mice Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Asia-Pacific 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Asia-Pacific 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Asia-Pacific 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Asia-Pacific 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Australia 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Australia 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 185: Australia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Australia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Australia 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • INDIA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 188: India Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: India 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 191: India Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: India 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 194: India Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: India Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: India 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: South Korea 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: South Korea 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 203: South Korea Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: South Korea Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: South Korea 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Asia-Pacific Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Asia-Pacific 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Mice Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Latin America 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Latin America 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Latin America 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 224: Latin America Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Latin America Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Latin America 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Argentina 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Argentina 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 233: Argentina Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Argentina Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Argentina 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Brazil 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Brazil 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 242: Brazil Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Brazil Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Brazil 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Mexico 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Mexico 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 251: Mexico Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Mexico Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Mexico 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Rest of Latin America 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Rest of Latin America 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Rest of Latin America Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Rest of Latin America 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Mice Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Middle East 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Middle East 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Middle East 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 272: Middle East Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Middle East Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Middle East 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Iran 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: Iran 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 281: Iran Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Iran Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: Iran 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: Israel 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: Israel 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 290: Israel Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Israel Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: Israel 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: Saudi Arabia 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: Saudi Arabia 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Saudi Arabia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Saudi Arabia 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: UAE 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 307: UAE 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 308: UAE Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 309: UAE Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 310: UAE 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 313: Rest of Middle East 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 316: Rest of Middle East 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 318: Rest of Middle East Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 319: Rest of Middle East 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • AFRICA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 322: Africa 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 325: Africa 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 326: Africa Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 327: Africa Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 328: Africa 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제